DNA methyltransferase inhibitors (DNMTi) approved for older AML patients are clinically
tested in combination with histone deacetylase inhibitors (HDACi). The mechanism of action …

Frequent genetic alterations in hematopoietic neoplasias (chromosomal translocations,
point mutations, etc.) have provided biologic targets for the development of effective novel …

The three DNA methyltransferase (DNMT)-inhibiting cytosine nucleoside analogues,
azacitidine, decitabine and zebularine, which are currently studied as nonintensive therapy …

DNA methylation and histone modification are epigenetic mechanisms that result in altered
gene expression and cellular phenotype. The exact role of methylation in myelodysplastic …

DNA methyltransferase inhibitors (DNMTi) decitabine and azacytidine are approved
therapies for myelodysplastic syndrome and acute myeloid leukemia, and their …

Background Aberrant DNA methylation has been identified as a key molecular event
regulating the pathogenesis of myelodysplastic syndromes (MDS); myeloid neoplasms with …

DNA methylation inhibitors such as 5-aza-2′-deoxycytidine (5-Aza-CdR) are currently used
for the treatment of myelodysplastic syndrome. Although global DNA demethylation has …

Abstract Purpose: Azanucleoside DNA methyltransferase (DNMT) inhibitors are currently
approved by the US Food and Drug Administration for treatment of myelodysplastic …

Background Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are
neoplastic disorders of hematopoietic stem cells. DNA methyltransferase inhibitors, 5 …

Azanucleoside drugs such as 5-azacytidine (Vidaza) and 5-aza-2′-deoxycytidine
(decitabine, Dacogen) function as DNA methyltransferase inhibitors in vitro and represent …